An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: Potent antitumoral efficacy but no toxicity to normal cell

Cancer Research

Volumn 62, Issue 12, 2002, Pages 3438-3447

  Tsukuda, Kazunori ^a   Wiewrodt, Rainer ^a   Molnar Kimber, Katherine ^a   Jovanovic, Vuk P ^a   Amin, Kunjlata Manibhai ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR E2F;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL KILLING; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; ENDOTHELIUM CELL; FIBROBLAST; GENE ACTIVATION; GENE ACTIVITY; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOCARCINOMA; ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CYTOPATHOGENIC EFFECT, VIRAL; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; FEMALE; FIBROBLASTS; HELA CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; OVARIAN NEOPLASMS; PROMOTER REGIONS (GENETICS); TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037096881     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Update on adenovirus vectors and its vectors
2. Cancer gene therapy: Hard lessons and new courses
3. Replicative adenoviruses for cancer therapy
4. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
5. Oncolytic biotherapy: A novel therapeutic platform
6. Toward a new generation of conditionally replicating adenoviruses: Pairing tumor selectivity with maximal oncolysis
7. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer
8. The emerging fields of suicide gene therapy and virotherapy
9. Targeting adenoviruses
10. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
11. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
12. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts
13. Clinical research results with d1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned?
14. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer
15. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene and radiotherapy
16. Adenovirus lacking the 19-kDa and 55-kDa E1B genes exerts a marked cytotoxic effect in human malignant cells
17. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas
18. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
19. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy
20. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
21. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
22. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts
23. A hepatocellular carcinoma-specific a adenovirus variant, CV890, eliminates tumor cells in combination with doxorubicin
24. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
25. A conditional replicationcompetent adenoviral vector. Ad-OC-E1a, to co target prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis
26. Selectivity of a replication competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen
27. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines
28. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression
29. Expression analysis using DNA microarrays demonstrates that E2F-1 up-regulates expression of DNA replication genes including replication protein A2
30. The regulation of E2F by pRB-family proteins
31. p16 (MTS-1/CDKN2/INK4a) in cancer progression
32. The Pezcoller Lecture: Cancer cell cycles revisited
33. E2F-1: A proliferative marker of breast neoplasia
34. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase
35. Distinct pattern of E2F1 expression in human lung tumors: E2F1 is upregulated in small cell lung carcinoma
36. The gene expression index c-myc x E2F-1/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells
37. Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line
38. The cellular effects of E2F overexpression
39. Tumor-selective transgene expression in vivo mediated by an E2Fresponsive adenoviral vector
40. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma
41. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy
42. Tumor necrosis factor α activates NF-κB in acid sphingomyelinase-deficient mouse embryonic fibroblasts
43. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter
44. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties
45. A TATA box implicated in E1A transcriptional activation of a simple adenovirus 2 promoter
46. Induction of the cellular E2F-1 promoter by the adenovirus E4 protein
47. Replicating adenoviruses that target tumors with constitutive activation of the wnt-signaling pathway
48. Wild-type adenovirus decreases tumor xenograft growth: But despite viral persistence complete tumor responses are rarely achieved-deletion of the viral E1b-19kD gene increases the viral oncolytic effect
49. Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector
50. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy
51. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
52. Cationic liposomemediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial
53. Mutantadenoviruses selectively replication-competent in tumor cells
54. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency
55. Reengineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy
56. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the ADP region
57. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
58. Induced apoptosis supports spread of adenovirus vectors in tumors